A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemia
J. L. Marin-Rubio, R. E. Heap, T. Heunis…·M. Trost
This study identifies nilotinib as an anti-inflammatory drug using a MALDI-TOF assay in AML-derived monocytes, showing it inhibits the p38-MK2/3 signaling axis.